NCT05564416 2025-10-21
Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial
National Cancer Institute (NCI)
Phase 2 Withdrawn
Clinical Trials
5 trialsNCT06424717 2024-09-27
Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)
EMD Serono
Phase 2 Withdrawn
NCT04040725 2019-12-17
Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT01907308 2014-04-29
Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma
University of Colorado, Denver
Phase 2 Withdrawn
NCT01700010 2013-01-17
Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer
University of Michigan Rogel Cancer Center
Phase 2 Withdrawn